PTGX
Protagonist Therapeutics, Inc.Healthcare · $9.2B market cap
Verdict
We can't put a fair value on PTGX right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.
Business quality
2 of 5 clear the 10% bar. What are the Big Five?
Follow PTGX
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
1 of the investors we track holds PTGX. In Q1 2026, 1 added. Who we track
Moves in Q1 2026
Added: Polen Capital Management
Insider activity
Since Sep 3, 2026: no open-market purchases, 3 sales worth $18.2M and 4 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
PATEL DINESH V PH D
President and CEO · 2026-09-10
Sold
$1.0M
PATEL DINESH V PH D
President and CEO · 2026-09-09
Sold
$9.3M
PATEL DINESH V PH D
President and CEO · 2026-09-08
Sold
$7.9M
Other filings
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works